Pay in 4 interest-free payments of $6.94 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
Key Takeaway The NICE 2026 update highlights a shift from purely glycaemic control to early cardiovascular and renal protection, supporting the earlier use of SGLT2 inhibitors and GLP-1based therapies in appropriate patients
In part, this comes from a lifetime of sun exposure, but it's also a natural aspect of getting older
The medication typically requires dose escalation over several months to reach therapeutic levels while minimizing gastrointestinal side effects
GLP-1 and GIP/GLP-1 medications have boxed warnings regarding thyroid C-cell tumors (contraindicated in patients with personal/family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2) and carry risks of pancreatitis, gallbladder disease, and diabetic retinopathy progression
